Expert Interview
A 2nd look at the developing landscape for children with achondroplasia including the Phase 3 PROPEL 3 data of oral infigratinib from BridgeBio and the 52-week COACH data of TransCon CNP with TransCon hGH from Ascendis
Ticker(s): ASND, BBIOInstitution: Hôpital Femme-Mère-Enfant
- Professor of Pediatrics and Head of the Division of Pediatric Endocrinology at Hôpital Femme-Mère-Enfant (Lyon, France)
- Treats ~12 patients with achondroplasia.
- Research focuses on a variety of endocrinological conditions in children and was a co-author on the PROPEL studies of Infigratinib in Children with Achondroplasia.
On a scale of 1 to 10 (with 10 being ecstatic), how excited are about the 52-week COACH data of TransCon CNP with TransCon hGH and its potential as a treatment for children with achondroplasia?
Added By: sara_adminHow many child patients do you manage with achondroplasia?
Added By: sara_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for oral Infigratinib therapy as a potential treatment for children with achondroplasia?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Mar 10, 2026
- Call Time
- 10:00 AM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
